Biocryst Pharmaceuticals, Inc. · NASDAQ:BCRX
Biocryst Pharmaceuticals — Q2 2023 Earnings Presentation
8 slides from Biocryst Pharmaceuticals's earnings presentation, Aug 3, 2023
Slide 1: Second Quarter 2023 Results Call
Second Quarter 2023 Results Call Corporate Update & Financial Results August 3, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain
Slide 3: Agenda
Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ ORLADEYO® (berotralstat) Launch Update: Charlie Gayer – Chief Commercial Officer ◆ Pipeline Update: Dr. Helen Thackray – Chief Research and Development Officer ◆ Financial Update: Anthony Doyle – Chief Financial Offi
Slide 4: Orladeyo Pediatric Trial Enrollment Ongoing
Orladeyo Pediatric Trial Enrollment Ongoing New granule formulation designed to reduce burden of therapy for children with HAE Trial Details • Ages 2 to <12 • Enrollment of approximately 20 patients (4 cohorts) • 12-week standard-of-care therapy, followed by open- label treatment period • Primary en
Slide 5: Debt Refinancing: Better Terms, Longer Maturity, Larger Principal
Debt Refinancing: Better Terms, Longer Maturity, Larger Principal New Terms (Pharmakon) Prior Terms (Athyrium) Principal Drawn $300M $200M Tranches Available $150M None (at company option) (through September 2024) 3 mo. SOFR + 7.00% 3 mo. LIBOR (3.50% cap) + 8.25% Rate With PIK option: + 7.25% With
Slide 6: Finance Summary
Finance Summary (figures in millions) Q2 2023 Cash Position Cash, cash equivalents, restricted cash & investments at December 31, 2022 $444 Cash, cash equivalents, restricted cash & investments at June 30, 2023 $416 Senior credit facility A $304 2023 FY Guidance ORLADEYO® revenue ≥$320 Operating exp
Slide 7: Save the Date: BioCryst Pharmaceuticals R&D Day
Save the Date: BioCryst Pharmaceuticals R&D Day November 3, 2023 7
Slide 8: Second Quarter 2023 Results Call
Second Quarter 2023 Results Call Corporate Update & Financial Results August 3, 2023
BioCryst Pharmaceuticals — Q2 2023 Earnings Presentation on 6ix